Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
Aldeyra drops and swaps RASP assets in response to data
Aldeyra stopped work on one asset in the wake of phase 2 data and swapped out two other molecules in response to recent results.
Nick Paul Taylor
Oct 28, 2025 9:10am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen
Aug 29, 2025 10:59am
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
GSK pays $1.2B upfront for Boston's lead liver disease drug
May 14, 2025 2:53am
NGM Bio cuts 75% of staff, halts midstage liver disease program
May 12, 2025 7:00am
